Trial Profile
An Open-Label, Single Arm Phase II Study of Nivolumab in Combination With Ipilimumab in Subjects With Advanced Neuroendocrine Tumors
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Jan 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Carcinoid tumour; Colorectal cancer; Lung cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- 22 Nov 2022 Status changed from active, no longer recruiting to discontinued.
- 26 May 2022 Planned primary completion date changed from 1 May 2022 to 1 May 2023.
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology